Given that disruptions in YME1L1 have been linked to impaired mitochondrial structure and increased production of reactive oxygen species (ROS), its upregulation in Basal tumors may support the high metabolic demands and proliferative capacity of these cancer cells [72]. This evidence concerns the gene YME1L1 and cancer.